Medication info

Glymet Tablet 50/850 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Sitagliptin Phosphate Hydrate›64.25mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Withus Pharmaceutical Co., Ltd.
Appearance
Pink oval film-coated tablet
Packaging
56 tablets (28 tablets/PTP*2)
Approval status
Expired

MFDS item code 201505750 · Approved 2015.08.18

This product's status changed to Expired on 2025.08.18. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of blood glucose control in patients with type 2 diabetes
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with food. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The starting dose of this drug should be determined based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the starting dose of this drug is 1 tablet of 50/500 mg twice daily; the dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, 2. Patients Who Should Not Receive This Drug). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended starting dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose. - Patients switching to this drug from concomitant sitagliptin and metformin therapy may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with concomitant metformin and sulfonylurea, metformin and insulin, or metformin and thiazolidinedione therapy: The starting dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the starting dose of metformin should be determined based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this drug in patients previously treated with another oral antidiabetic drug. Since any change in the treatment regimen for type 2 diabetes may result in changes in blood glucose control, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Should Not Receive This Drug).

Ingredients

Manufacturer
Withus Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in patients with type 2 diabetes

View approved original text

This drug is used to improve blood sugar control in patients with type 2 diabetes by assisting with diet and exercise.

How to take

Adult dose

For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with food. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The starting dose of this drug should be determined based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the starting dose of this drug is 1 tablet of 50/500 mg twice daily; the dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, 2. Patients Who Should Not Receive This Drug). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended starting dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose. - Patients switching to this drug from concomitant sitagliptin and metformin therapy may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with concomitant metformin and sulfonylurea, metformin and insulin, or metformin and thiazolidinedione therapy: The starting dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the starting dose of metformin should be determined based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this drug in patients previously treated with another oral antidiabetic drug. Since any change in the treatment regimen for type 2 diabetes may result in changes in blood glucose control, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Should Not Receive This Drug).

Precautions

This drug contains two ingredients, sitagliptin and metformin. Firstly, sitagliptin can rarely cause serious allergic reactions, which may occur within 3 months of taking the medication. If symptoms such as skin rash, difficulty breathing, swelling of the face or lips appear, discontinue this medication immediately and consult a doctor. Additionally, sitagliptin can cause inflammation of the pancreas, known as acute pancreatitis, so if symptoms such as abdominal pain, nausea, or vomiting occur, seek medical attention immediately. Metformin can cause lactic acidosis, a rare but serious metabolic anomaly. This symptom can begin with nonspecific symptoms such as muscle pain, difficulty breathing, severe fatigue, and abdominal pain, so if these symptoms occur, stop taking the medication immediately and visit a hospital. Patients with poor kidney function or liver dysfunction should not take this medication and should undergo regular kidney function tests. This medication is not used in patients with moderate to severe renal impairment, severe infections, heart failure, acute myocardial infarction, severe dehydration, or in pregnant or breastfeeding women. Also, this medication should be temporarily discontinued before using tests that involve iodine contrast agents and should not be resumed until kidney function is confirmed to be normal. There is a risk of hypoglycemia with this medication, so caution is advised if meals are skipped or if exercise suddenly increases, and hypoglycemia symptoms may be more pronounced when used in combination with other antidiabetic agents. While taking this medication, side effects such as diarrhea, nausea, vomiting, headache, and upper respiratory infections may occur, and rarely severe joint pain or skin conditions may arise, so any unusual symptoms should be reported to a doctor. Alcohol can increase the risk of side effects from this medication, so excessive drinking should be avoided while on treatment. Finally, this medication is not recommended for children under 18, pregnant women, or breastfeeding mothers, and elderly patients should have their kidney function monitored regularly while adjusting the dosage. While taking this medication, it is important to regularly check blood sugar levels, kidney function, and vitamin B12 levels, and to consult healthcare professionals immediately if any unusual symptoms arise.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
  • nausea
Show 24 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • vitamin B12 deficiency
  • dermatitis
  • anorexia
  • weight loss
  • dyspnea
  • unstable angina
  • dizziness
  • acute renal failure
  • decreased appetite
  • gastrointestinal disorders
  • itching

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air exposure, at room temperature between 1 to 30 degrees Celsius. Proper storage will help maintain the efficacy of the medication for a longer period.

Appearance and packaging

Appearance

Pink oval film-coated tablet

Package unit

56 tablets (28 tablets/PTP*2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.